Pressroom
-
Erin Trish Appointed Co-Director of USC Schaeffer Center
Erin Trish, a health economist whose work focuses on the intersection of public policy and healthcare markets, has been named co-director of the Schaeffer Center.
-
Kids and Cannabis: California Dispensaries Lack Adequate Screening to Keep Out Minors, USC-UCSD study finds
The study of 700 licensed cannabis dispensaries found many retail locations have inadequate screening processes.
Categorized in -
COVID-19 Vaccine Refusal Increases After Being Overlooked During Distribution Process
A new USC Schaeffer Center study finds that how vaccines are allocated may contribute to vaccine hesitant individuals later refusing the vaccine when it is made available to them.
Categorized in -
Multi-Cancer Blood Tests Can Reduce Late-Stage Cancer Diagnosis in Black and Latino Patients
A new white paper published by the USC Schaeffer Center focuses on the potential benefit of multi-cancer early detection (MCED) blood-based tests to reduce disparities in late-stage cancer diagnosis among minority populations.
Categorized in -
COVID-19 Vaccination Mandates for Employees and Students are Effective Tool Against Virus Spread
A new white paper finds private sector influence combined with market-side demand for mandates will overcome state laws that have limited vaccine requirements thus far.
Categorized in -
Latinos Are More Likely to Die From COVID-19, Underlining Racial and Ethnic Disparities in Outcomes
Latinos were tested more for COVID-19 and had higher rates of infection, hospitalization and death.
Categorized in -
Risk of Losing Cash Reward Strongly Impacts Exercise Habit
Researchers found adults were incentivized to exercise more often for the same anticipated cash reward simply by changing how the reward is delivered.
Categorized in -
USC Research Shows Costco Beats Medicare in Generic Drug Savings Nearly 50% of the Time
Intermediaries negotiate good prices, but lack incentives to pass savings to beneficiaries and taxpayers.
Categorized in -
USC Study Finds When Medicare Chips in for Hepatitis C Treatment for Medicaid Patients, Everyone Wins
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years
Categorized in -
New Schaeffer Center White Paper Explains Complicated Relationship Between FDA Approvals and Future Innovation
The relationship between approvals and future innovation is unclear at best. As such, the FDA should continue to base its decisions solely on safety and efficacy, rather than speculative long-term innovation effects.
Categorized in